Hilo by Aktiia
Aktiia, now trading under Hilo, was established in 2018 to transform how blood pressure is measured and therefore managed. Hilo is transforming blood pressure monitoring with cuffless, AI-powered technology that delivers continuous, accessible insights for individuals and healthcare professionals. Our foundation model is trained on billions of optical signals and hundreds of millions of readings from over 120,000 users—one of the largest datasets in the field. Backed by a multidisciplinary team with deep expertise in biomedical signal processing, Hilo has contributed to over 120 peer-reviewed publications and holds more than 35 patents. Headquartered in Switzerland, we’re expanding globally to redefine how blood pressure is measured and managed.
Hilo by Aktiia
Aktiia, now trading under Hilo, was established in 2018 to transform how blood pressure is measured and therefore managed. Hilo is transforming blood pressure monitoring with cuffless, AI-powered technology that delivers continuous, accessible insights for individuals and healthcare professionals. Our foundation model is trained on billions of optical signals and hundreds of millions of readings from over 120,000 users—one of the largest datasets in the field. Backed by a multidisciplinary team with deep expertise in biomedical signal processing, Hilo has contributed to over 120 peer-reviewed publications and holds more than 35 patents. Headquartered in Switzerland, we’re expanding globally to redefine how blood pressure is measured and managed.
TL;DR
Product: Cuffless, wrist-worn optical blood pressure monitor and analytics platform (Hilo/Aktiia G0)
Recent raise: $42M Series B (announced May 1, 2025)
Founded / HQ: Founded in Switzerland; headquartered in Neuchâtel
Regulatory / scale signals: Reported regulatory approvals (CE, Canada, Australia, Saudi Arabia) and 120,000+ devices sold
Related Companies
| Company |
|---|
 |
 |
 |
 |
 |
Company Overview
Problem Domain
Hypertension monitoring and management
Industry
Healthtech / Medtech
Funding Track Record
$42M
Described as oversubscribed
CHF 27M (~USD 30M)
Participation from Khosla Ventures, Molten, Translink Capital, Verve, and 415 Capital
Investor Signal
“Participation from prominent health/VC investors including Earlybird Health, Wellington Partners, Redalpine, Khosla Ventures”